SpyGlass Pharma, Inc. Financial Instrument Mandatorily Redeemable Liability Classified Settlement Amount
SpyGlass Pharma, Inc. (SGP) reported Financial Instrument Mandatorily Redeemable Liability Classified Settlement Amount of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Other Liabilities and Financial Instruments Subject to Mandatory Redemption
us-gaap:FinancialInstrumentMandatorilyRedeemableLiabilityClassifiedSettlementAmount · last filed 2026-08-06
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for the quarter ending 2026-06-30 was $0.00.
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for the quarter ending 2025-06-30 was $0.00.
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for the quarter ending 2025-03-31 was $4.94M.
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for fiscal 2025 was $4.94M.
- SpyGlass Pharma, Inc. financial instrument mandatorily redeemable liability classified settlement amount for fiscal 2024 was $0.00.
| Period end | Financial Instrument Mandatorily Redeemable Liability Classified Settlement Amount 3 month | Financial Instrument Mandatorily Redeemable Liability Classified Settlement Amount 6 month | Financial Instrument Mandatorily Redeemable Liability Classified Settlement Amount 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $4.94M 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.94M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $4.94M 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |